Extended Data Fig. 6: Elovl1-deficient CD8+ T cells present stronger TCR signalling and activation.
a, Quantification of total lipid species by LS-MS standard lipidomics in in vitro-activated OT-I T cells treated with DMSO or C3 (n=5). For each lipid species, the contribution of fatty acids with different chain lengths is shown. The statistic is applied to the total quantity of lipids in each species. SM= sphingomyelins; Cer= Ceramides; TG= triacylglycerides; DG= diacylglycerides; PC= phosphatidylcholine; PE= phosphatidylethanolamine; PG= phosphatidylglycerol; PI= phosphatidylinositol; PS= phosphatidylserine. b, c, Representative real-time proliferation curves (b) and quantification of growth (% of confluence at t60h - % of confluence at t20h) (c) of naive murine CD8+ T cells stimulated with anti-CD3/anti-CD28 activation beads in the presence of ELOVL1 inhibitor (C3) in T cell media (n=4, two independent experiments). (c) Exact p value = 0.000006. d, e, Representative real-time proliferation curves (d) and quantification of growth (% of confluence at t80h- % of confluence at t10h) (e) of naive human CD8+ T cells stimulated with anti-CD3/anti-CD28 activation beads in the presence of ELOVL1 inhibitor (C3) (n=3, two independent experiments). f, Flow cytometry quantification of membrane cholesterol with FILIPIN III in ELOVL1 inhibitor (C3) and vehicle (DMSO) treated human CD8+ T cells at day 7 from in vitro activation (n=3). Data are presented as the mean ± s.e.m. Statistical significance was assessed by two-tailed unpaired (a, c, e) or paired (f) Student’s t-test.
